Pharmacovigilance and its impact on drug safety
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20261976Keywords:
Pharmacovigilance, Drug safety surveillance, Thalidomide crisis, Pharmacovigilance programme of IndiaAbstract
Pharmacovigilance is the science and activities concerned with the detection, assessment, understanding, and prevention of adverse effects or any other drug related problems. Pre-marketing clinical trials provide essential information on efficacy and safety of drugs. they are limited by small sample size and short durations which makes post-marketing surveillance crucial for identifying, rare, serious and long-term adverse drug reactions. Pharmacovigilance systems rely on spontaneous reporting, active surveillance and pharmacoepidemiological studies to generate safety signals and support regulatory decision making. Effective pharmacovigilance contributes to the rational use of medicines, enhances patient safety, and improves public health outcomes through continuous monitoring of benefit-risk ratio of medicinal products. Strengthening reporting systems and increasing awareness among healthcare professionals and patients remain key to improving pharmacovigilance practices globally.
References
World Health Organization. Looking at pharmacovigilance: ensuring the safe use of medicines: WHO policy perspectives on medicines. 2004. Available at: https://www.who.int/publica tions/i/item/WHOEDM2004.8. Accessed on 02 March 2026.
Sindhu S. Principles of pharmacovigilance and ADR reporting system. In: CBME pharmacology skills OSPE practical DOAP as per recommendations of UG curriculum. MCI. 2018;1:58-9.
World Health Organization. Safety of medicines in public health programmes: pharmacovigilance, an essential tool. 2006. Available at: https://www.who. int/publications/i/item/9241593911. Accessed on 02 March 2026.
Klepper MJ. The periodic safety update report as a pharmacovigilance tool. Drug Saf. 2004;27:569-78.
Livio F, Renard D, Buclin T. Pharmacovigilance. Rev Med Suisse. 2012;8:116-9.
World Health Organization. Looking at pharmacovigilance: ensuring the safe use of medicines: WHO policy perspectives on medicines. 2004. Available at: https://www.who.int/publications/ i/item/WHOEDM2004.8. Accessed on 02 March 2026.
Skalli S, Soulaymani Bencheikh R. Safety monitoring of herb-drug interactions: a component of pharmacovigilance. Drug Saf. 2012;35:785-91.
Maiti R. ADR monitoring and pharmacovigilance. Postgrad Topics Pharmacol. 2019;13:213-4.
Chaurasia RC. To recognize and report an adverse drug reaction. In: Competency based pharmacology practical exercises. 2025:116-7.
Yadav A. Principles of pharmacovigilance and ADR reporting system. In: Competency based pharmacology manual for MBBS students. 2003. Available at: https://www.scribd.com/document/ 899297765/Arvind-Yadav-Competency-Based-Pharmacology-Manual-for-MBBS-Students-2021-Libgen-li. Accessed on 02 March 2026.
Sartori D, Aronson JK, Onakpoya IJ. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature. Syst Rev. 2020;9(1):180.
Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL, Turner MA, Young B. What can we learn from parents about enhancing participation in pharmacovigilance? Br J Clin Pharmacol. 2013;75(4):1109-17.
Rani ASTC, Kasukurthi SR, Bhuvaneshwari E, Marpaka S. A cross-sectional, questionnaire-based study on knowledge, attitude, and practice of pharmacovigilance among post-graduates at a tertiary care teaching hospital, Telangana. Int J Basic Clin Pharmacol. 2002;11(3):242-8.
Cervantes-Arellano MJ, Castelán-Martínez OD, Marín-Campos Y, Chávez-Pacheco JL, Morales-Ríos O, Ubaldo-Reyes LM. Educational interventions in pharmacovigilance to improve the knowledge, attitude and the report of adverse drug reactions in healthcare professionals: Systematic Review and Meta-analysis. Daru. 2024;32(1):421-34.
Garcia-Abeijon P, Costa C, Taracido M, Herdeiro MT. Factors associated with underreporting of adverse drug reactions by healthcare professionals: a systematic review update. Drug Saf. 2023;46:625-36.